← Back to home

MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19)

Clinical trials for MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19) explained in plain language.

Never miss a new study

Get alerted when new MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19) trials appear

Sign up with your email to follow new studies for MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental cell therapy offers hope for kids with rare COVID-Linked syndrome

Disease control NO_LONGER_AVAILABLE

This study provided early access to an experimental treatment called remestemcel-L for children aged 2 months to 17 years with MIS-C, a severe inflammatory condition linked to COVID-19. The goal was to see if the therapy could safely reduce inflammation and improve outcomes. The …

Matched conditions: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19)

Sponsor: Mesoblast International Sàrl • Aim: Disease control

Last updated May 13, 2026 16:01 UTC

MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19)

Get alerted when new MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19) trials appear

Experimental cell therapy offers hope for kids with rare COVID-Linked syndrome